OncoMatch/Clinical Trials/NCT06807632
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
Is NCT06807632 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Valemetostat and Atezolizumab for extensive-stage small-cell lung cancer.
Treatment: Valemetostat · Atezolizumab — This study will test whether valemetostat in combination with atezolizumab is a safe treatment that causes few or mild side effects in people with extensive-stage small cell lung cancer (SCLC). The researchers will test different doses of valemetostat to find the highest dose that causes few or mild side effects in participants. After the dose is found, researchers will test it in a new group of participants to learn more about the safety of the study treatment and see if it is an effective treatment for extensive-stage SCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IV
Radiographically documented RECIST version 1.1 stable disease, partial or complete response after initial treatment with a platinum doublet regimen in combination with atezolizumab for 4 cycles. It is acceptable to have no measurable disease at the start of this study.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
initial treatment with a platinum doublet regimen in combination with atezolizumab for 4 cycles
Must have received: anti-PD-L1 therapy (atezolizumab) — first-line
initial treatment with a platinum doublet regimen in combination with atezolizumab for 4 cycles
Cannot have received: valemetostat or other EZH2 inhibitor
Prior exposure to valemetostat or other inhibitors of enhancer of zeste homologue-2 (EZH2)
Cannot have received: consolidative chest radiation
Patients who receive consolidative chest radiation after completion of initial chemotherapy and immunotherapy
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L (1500/µL); Hemoglobin ≥ 9 g/dL; Platelets ≥ 100 x 10^9/L
Kidney function
Creatinine clearance ≥ 30 mL/min as calculated using the Cockcroft-Gault equation
Liver function
AST, ALT, and alkaline phosphatase (ALP) ≤ 3 x ULN; if liver metastases: AST, ALT and ALP ≤ 5 x ULN
Cardiac function
No evidence of prolongation of QT/QTc interval (QTcF >470 ms); no myocardial infarction within 6 months; no uncontrolled angina pectoris within 6 months; no NYHA Class 3 or 4 congestive heart failure; no uncontrolled hypertension (resting systolic BP >160 mmHg or diastolic BP >100 mmHg)
Adequate hematologic and end-organ function, as defined by the following laboratory test results obtained within 14 days prior to initiation of study treatment. ... Adequate bone marrow function as defined by: Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1500/µL); Hemoglobin ≥ 9 g/dL; Platelets ≥ 100 x 10^9/L o Adequate renal function as defined by: Creatinine clearance ≥ 30 mL/min as calculated using the Cockcroft-Gault equation o Adequate hepatic function as defined by: AST, ALT, and alkaline phosphatase (ALP) ≤ 3 x ULN with the following exception: Patients with documented liver metastases: AST, ALT and ALP ≤ 5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify